First AD

Second AD

Genitourinary Cancers

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research. 

Immuno-Oncology

Revolutionary Advances for Treating Urothelial Carcinoma

OncLive News Network®

Bladder Cancer: Paradigm Changing Advances in Treatment

Durvalumab FDA Approval for Bladder Cancer

Historic Perspective on Bladder Cancer Treatment

Frontline Atezolizumab for Advanced Bladder Cancer

FDA Approval of Durvalumab for Bladder Cancer

Treatment of Bladder Cancer-Immune Checkpoint Inhibitors

FDA Approval of Durvalumab for Advanced Bladder Cancer

 Promising Treatment Options for Advanced Bladder Cancer

Immune Checkpoint Inhibitors for Advanced Bladder Cancer

Durvalumab for Treatment of Advanced Bladder Cancer

Future Treatment Options for Advanced Bladder Cancer

Use of Immune Checkpoint Inhibitors for Bladder Cancer

Highlights of Durvalumab for Advanced Bladder Cancer

Combination Therapies for Advanced Bladder Cancer